Spironolactone, 3-(3-oxo-7a-acetylthio-17b-hydroxy-4-androsten-17a-yl)propionic acid g-lactone (SPN), is a competitive aldosterone antagonist, which is used as a potassiumsparing diuretic in premature infants to reduce lung congestion.
The stability of SPN in solution was reported by Pramar and Gupta. In the study, SPN was most stable at pH 4.5, and the degradation rate increased with increasing and decreasing pH. The apparent first-order rate constant of SPN at 40°C in pH 7.3 buffer solutions was 8.3ϫ10 Ϫ4 h
Ϫ1
. 4 ) SPN degradation seemed to be a type of hydrolysis. We previously reported that the degradation of (Me)Arg-Lys-Pro-Trp-tertLeu-Leu-OEt (NT-1) and nikkomycin Z, which were hydrolyzed in the solution, were accelerated in rat plasma. [5] [6] [7] [8] We therefore theorized that SPN degradation might also be accelerated in rat plasma. However, the stability of SPN in rat plasma has not been reported, and the blood, serum, and plasma samples in the pharmacokinetic studies were treated without considering the stability of SPN in the samples. If SPN in the samples is unstable, the pharmacokinetic data reported are believed to be incorrect. We therefore began a study into SPN stability in rat plasma.
In this report, SPN stability in rat plasma is first described, and then the pharmacokinetic SPN data is shown in rats after an intravenous administration of 20 mg/kg obtained with temperature strictly controlled for plasma and blood samples.
MATERIALS AND METHODS
Materials Spironolactone (SPN) and canrenone (CAN) were purchased from Sigma Chemical Company (St. Louis, MO, U.S.A.) and Steraloids, Inc. (Newport, RI, U.S.A.), respectively. Sodium fluoride (NaF) of special reagent grade was obtained from Wako Pure Chemical Industries (Japan). Other chemicals were of reagent or HPLC grade.
Measurement of Stability in Rat Plasma
SPN was dissolved in ethanol to make a 1 mg/ml solution. Male SpragueDawley rat plasma previously prepared and stored at Ϫ80°C was used to measure the kinetics of SPN degradation. The pH value of the rat plasma was 7.8 at the start and the end of each experiment. The concentration of NaF in the plasma was 20 mg/ml. Immediately before each experiment, suitable aliquots of the plasma with or without NaF were pre-incubated for 15 min at 0°C, 23.5°C, and 37°C. The experiments were performed at 0-1°C, 23.5Ϯ0.5°C, and 37Ϯ0.5°C. Those temperatures were employed as the lowest temperature for treatment of plasma samples, usual room temperature, and body temperature, respectively. The experiments were initiated by adding the SPN solution to produce a final concentration of 20 mg/ml. A 200 ml aliquot of methanol containing 0.2% HClO 4 was added to 100 ml of sample solution immediately after it was taken from the reaction mixture, and cooled in an ice-bath. The mixture was stirred in a vortex mixer for 30 s and centrifuged at 3000 rpm for 10 min; 50 ml of the supernatant was injected into the chromatograph.
Determination of SPN in Rat Plasma by HPLC The concentration of SPN in plasma was determined with an HPLC assay consisting of a Model LC-9A pump, equipped with a Model SCL-6B system controller, a Model SPD-6A UV spectrophotometric detector, a Model CTO-6A column oven, a Model C-R4AX Chromatopac, and a Model SIL-6B autoinjector, all from Shimadzu (Kyoto, Japan). The mobile phase was acetonitrile-water-perchloric acid (60%)-sodium perchlorate monohydrate (485 : 515 : 1 : 5, v/v/v/w). The chromatographic column was a YMC Pack AM312 ODS (150 mmϫ6 mm I.D., particle diameter 5 mm) obtained from YMC Co. Ltd. (Kyoto). The flow rate, determination wavelength, and temperature of the column were 1 ml/min, 254 nm and 40°C, respectively.
Determination of CAN in Rat Plasma by HPLC The
The stability of spironolactone (SPN) in rat plasma was studied and its degradation was found to be an apparent first-order reaction. The apparent first-order rate constants (k obs ) at 37, 23.5 and 0°C were 3.543؎0.261 (h
؊1
, mean؎S.D., n‫,)3؍‬ 6.278؎0.045 (؋10 ؊1 h ؊1 ), and 7.336؎0.843 (؋10 ؊2 h ؊1 ), respectively. The half-lives were 0.20 h, 1.10 h, and 9.53 h. The degradation rate of SPN in rat plasma was markedly decreased when NaF, an esterase inhibitor, was added to the plasma, and the degradation was catalyzed by esterase in the plasma. These results indicated that not only plasma but also blood and serum samples in rat pharmacokinetic studies should be cooled to 0°C, the temperature maintained, and treated as soon as possible. In pharmacokinetic studies reported previously, the temperature control of plasma, blood, and serum samples was not described. The pharmacokinetic study in rats after intravenous administration of SPN at 20 mg/kg was performed with strict temperature control of plasma and blood samples. The AUC, MRT, CL and Vd ss values (mean؎S.E. of 4 rats) for SPN were 4100.8؎212.9 ng h/ml, 0.29؎0.01 h, 4915.7؎248.0 ml/h/kg, and 1435.4؎48.4 ml/kg, respectively. The AUC value was much larger than that previously reported. The AUC, MRT, C max and T max values (mean؎S.E. of 4 rats) of canrenone, an active metabolite of SPN, after the administration of SPN were 4196.1؎787.5 ng h/ml, 1.99؎0.13 h, 1546.3؎436.4 ng/ml and 1.0؎0.0 h, respectively. This AUC value was almost identical to the value previously reported.
Key words spironolactone; stability; rat plasma; determination method; pharmacokinetics; intravenous administration concentration of CAN in plasma was determined with an HPLC assay consisting of a Model LC-10AS pump, equipped with a Model SCL-10A system controller, a Model SPD-10A UV-VIS spectrophotometric detector, a Model CTO-10A column oven, a Model C-R7A Chromatopac, and a Model SIL-10A autoinjector, all from Shimadzu. The mobile phase was acetonitrile-water-perchloric acid (60%)-sodium perchlorate monohydrate (500 : 500 : 1 : 5, v/v/v/ w). The chromatographic column was a YMC Pack AM312 ODS (150 mmϫ6 mm I.D., particle diameter 5 mm) obtained from YMC Co., Ltd. The flow rate, determination wavelength, and temperature of the column were 1 ml/min, 300 nm and 40°C, respectively.
Animal Study Male Sprague-Dawley rats (SD rats) were used. All rats (310-343 g body weight) were allowed free access to water, but were fasted for 8 h after drug administration. SPN was dissolved in a solution (saline : ethanol, 1 : 1) to make solutions with a concentration of 10 mg/ml of SPN. Two ml/kg of the solution was injected into the right jugular vein after the rats had been lightly anesthetized with diethylether. The SPN dose was 20 mg/kg. Blood samples (0.3 ml) were withdrawn from the left jugular vein of the rats, immediately cooled in an ice-bath and centrifuged at 3000 rpm for 3 min to obtain plasma (0.12-0.15 ml). The plasma samples were immediately cooled in an ice-bath and the following treatment was carried out as soon as possible.
A 200 ml aliquot of methanol containing 0.2% HClO 4 was added to 100 ml of plasma sample and cooled in an ice-bath. The mixture was stirred in a vortex mixer for 30 s and centrifuged at 3000 rpm for 10 min; 50 ml of supernatant was injected into a chromatograph for SPN and CAN. All animal experiments were carried out according to the 'Guiding Principles for the Care and Use of Laboratory Animals, Hoshi University.'
Data Analysis Pharmacokinetic analysis of the plasma concentration data was performed using model-independent methods. The area under the plasma concentration-time curve (AUC ), total plasma clearance (CL), the mean residence time (MRT ) and the apparent volume of distribution at steady-state (Vd ss ) were calculated by a previously described method.
7) The peak plasma concentration (C max ) and the time taken to attain the peak concentration (T max ) were determined from the individual plasma concentration-time curves. Figure 1 shows the relationship between the residual percentage of SPN on a logarithmic scale and time at three different temperatures. This result indicates that the degradation rate of SPN in rat plasma at 37°C was very rapid and that the rate decreased with decreasing temperature, although the degradation reaction was observed even at 0°C. Each plot in Fig. 1 for 37, 23.5 and 0°C is linear. The degradation reaction of SPN within the range of 0 to 37°C is an apparent first-order reaction. The apparent first-order rate constant, k obs , was calculated from the slope of each straight line shown in Fig. 1 . The results are shown in Table 1 . The main degradation product of SPN in rat plasma was observed at about 4 min on the chromatogram when the retention times of SPN and CAN were 12.6 and 13.4 min, respectively. The concentration of the degradation product could not be found due to an unidentified peak and not having the standard compound for determination. The peak area of the degradation product at 5 min at 37°C corresponded to 3.17Ϯ0.33 mg/ml as SPN. The residual percentage of SPN was 65.9Ϯ4.3% at this time. At 0°C almost the same residual percentage, 63.1Ϯ2.2%, was observed at 6 h. The peak area of the degradation product was 3.21Ϯ0.09 mg/ml as SPN, which well agreed with the value at 5 min at 37°C. From this result, the reduction of the degradation rate of SPN with decreasing temperature was confirmed by the decrease in rate of producing of the degradation product.
RESULTS AND DISCUSSION

Stability of SPN in Rat Plasma
The apparent first-order rate constant at 40°C in pH 7.3 buffer solutions is reported to be 8.3ϫ10
Ϫ4 h
Ϫ1
. 4) The temperature and pH value were different from those in the rat plasma. The difference of the degradation rate between the buffer solutions at 40°C in pH 7.3 and at 37°C in pH 7.8 seemed to be small, and in the comparison of the degradation rates the value at 40°C in pH 7.3 was considered to be large. Therefore, the degradation rates were directly compared. The k obs at 37°C, 23.5°C and 0°C were about 4300, 760, and 88 times larger than the value at 40°C in pH 7.3 buffer solutions. The k obs at 37°C in rat plasma was markedly larger than the value at 40°C in pH 7.3 buffer solutions in spite of the higher temperature of the buffer solution. It was found from the results that the degradation reaction of SPN in rat plasma was catalyzed enzymatically. Figure 2 shows the effect of NaF on the degradation rate of SPN in rat plasma at 37°C. The effect of NaF on the k obs values at 0, 23.5, and 37°C is summarized in Table 1 . This result showed that the degradation of SPN was catalyzed by esterase in rat plasma. We previously reported the degradation rate of NT-1 6,7) and , respectively, while the k obs of SPN was smaller than NT-1 and nikkomycin Z. NT-1 and nikkomycin Z are catalyzed by esterase in plasma and SPN is also catalyzed by esterase. A detailed study of the degradation rates in plasma among different animal species is required in the future.
Pharmacokinetics of SPN in Rats
In a previously reported pharmacokinetic study of SPN using rats, the temperature control for blood and plasma or serum samples was not described clearly in the experimental section.
3) Accordingly, the plasma concentration of SPN might have been evaluated below the real concentration. We attempted to obtain real plasma concentrations and real pharmacokinetic parameters. Figure 3 shows the plasma concentration of SPN and CAN after an intravenous administration of SPN at 20 mg/kg. The pharmacokinetic parameters for SPN and CAN are summarized in Table 2 . The plasma levels of SPN appeared to decrease with time with a biexponential pattern. The elimination rate of SPN is very rapid, which was reflected in the small value of MRT (0.29 h) and in the large value of CL (4915.7 ml/h/kg). The AUC value and the concentration at 5 min, 4100.8 ng h/ml and 16065.3 ng/ml, were much higher than the values reported, 1628 ng h/ml and 6425 ng/ml, 3) respectively. On the other hand, CAN was detected in the plasma, and the AUC value for CAN was 4196.1 ng h/ml which agreed with the reported value, 4700 ng h/ml.
3)
The plasma concentration of SPN in our result is much higher and that of CAN is almost equal compared with the reported values, 3) suggesting that SPN in the samples was degraded, and that its determined concentration was lower than the real concentration. However, the reason for this difference is not clear, as there were some differences in the experimental conditions, for example, differences in the rats used and the administered solutions. We will study the pharmacokinetics of SPN in rats with plasma and blood samples under strict temperature control.
In conclusion, SPN was degraded in rat plasma, and this reaction was catalyzed by esterase in the plasma. The degradation rates at 37 and 23.5°C were rapid, which indicated that blood and plasma samples in rat pharmacokinetic studies should be cooled to 0°C, the temperature maintained, and treated as soon as possible. We also demonstrated the pharmacokinetic data obtained under strict temperature control for plasma and blood samples. A possibility of the degradation of SPN in samples of pharmacokinetic studies previously reported was suggested from these results. Vol. 28, No. 6 
